---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-090559"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:52:50.149507+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransCode receives two Nasdaq deficiency notices; faces potential delisting

## Summary
- On Aug 13, 2024, Nasdaq notified TransCode of minimum bid price deficiency; stock closed below $1.00 for 30 consecutive days.
- On Aug 15, 2024, Nasdaq notified of stockholders' equity deficiency; reported equity $1.32M vs $2.5M minimum.
- Company is ineligible for 180-day compliance period due to two reverse stock splits in prior 2 years with cumulative ratio >250:1.
- Company intends to request a hearing before Nasdaq Hearings Panel to stay any suspension/delisting action.
- Pro forma equity with $2.4M July 2024 offering is ~$3.7M, but Staff acceptance is uncertain.

## SEC filing metadata
- accession: 0001104659-24-090559
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924090559/0001104659-24-090559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924090559/tm2421945d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-090559
- JSON: https://secwatch.observer/filing/0001104659-24-090559.json
- Plain text: https://secwatch.observer/filing/0001104659-24-090559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.